Bob Langer-backed spin­out shoots for $75M-plus IPO while biotech SPACs con­tin­ue to rule on Wall Street

SQZ Biotech is look­ing to go pub­lic, squeez­ing its way on­to a long list of biotechs to hit Wall Street this year.

The Wa­ter­town, MA-based biotech filed on Fri­day for a $75 mil­lion IPO to de­vel­op its cell ther­a­pies, now the main fo­cus fol­low­ing a shift in pri­or­i­ties to pipeline build­ing. Num­ber 1 on its list of pri­or­i­ties is its Roche-part­nered anti­gen pre­sent­ing cell (APC) tech, which is cur­rent­ly in Phase I for HPV and sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER